文献速递前列腺癌

全血AR-V7预测转移性去势抵抗性前列腺癌阿比特龙或恩扎卢胺治疗反应

AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
PubMed 文献 · Eur Urol · 2017-08-14

研究对85例转移性去势抵抗性前列腺癌(mCRPC)患者治疗前全血行微滴数字PCR检测AR-V7,18%(15/85)高表达。高表达者无一例PSA应答,且PSA无进展生存、临床无进展生存和总生存均更短,多因素分析为独立预测因子。作者认为全血AR-V7检测简单有前景,但需前瞻性验证后才能用于临床。

要点

  • 全血可检测AR-V7 mRNA,无需循环肿瘤细胞捕获。
  • 高AR-V7表达者PSA应答率为0,为PSA应答独立预测因子(p=0.03)。
  • 高AR-V7表达与更短PSA-PFS、临床PFS和OS独立相关。

核心结论

  • 全血AR-V7 mRNA检测是预测mCRPC患者接受阿比特龙或恩扎卢胺治疗不良结局的简单且有前景的方法。
  • 作者指出该检测在应用于临床实践前需要前瞻性验证。

研究设计与样本

  • 前瞻性生物样本库中85例mCRPC患者,治疗开始前采集全血,其中阿比特龙组56例、恩扎卢胺组29例。
  • 采用微滴数字PCR检测全血AR-V7,分析其与PSA应答(PSA下降≥50%)、PSA无进展生存(PSA-PFS)、临床PFS和总生存(OS)的关联。

主要发现

  • 全血高AR-V7表达可检测于18%(15/85)的患者。
  • 高AR-V7表达患者无一例达到PSA应答,AR-V7状态是多因素logistic回归中PSA应答的独立预测因子(p=0.03)。
  • 高AR-V7表达与更短PSA-PFS相关(中位2.4 vs 3.7个月;p<0.001)。
  • 高AR-V7表达与更短临床PFS相关(中位2.7 vs 5.5个月;p<0.001)。
  • 高AR-V7表达与更短OS相关(中位4.0 vs 13.9个月;p<0.001)。

关键数值与推荐

  • 多因素Cox回归中,高AR-V7表达为更短PSA-PFS的独立预测因子(HR 7.0,95%CI 2.3-20.7;p<0.001)。
  • 多因素Cox回归中,高AR-V7表达为更短临床PFS的独立预测因子(HR 2.3,95%CI 1.1-4.9;p=0.02)。
  • 多因素Cox回归中,高AR-V7表达为更短OS的独立预测因子(HR 3.0,95%CI 1.4-6.3;p=0.005)。

临床怎么用

  • 作者认为全血AR-V7 mRNA检测是预测mCRPC患者接受阿比特龙或恩扎卢胺治疗不良结局的简单且有前景的方法。
  • 作者指出该检测在应用于临床实践前需要前瞻性验证。

局限性

  • 作者指出该检测在应用于临床实践前需要前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It has been demonstrated that androgen receptor splice variant 7 (AR-V7) expression in circulating tumor cells (CTCs) predicts poor treatment response in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone or enzalutamide. OBJECTIVE: To develop a practical and robust liquid profiling approach for direct quantification of AR-V7 in peripheral whole blood without the need for CTC capture and to determine its potential for predicting treatment response in mCRPC patients. DESIGN, SETTING, AND PARTICIPANTS: Whole blood samples from a prospective biorepository of 85 mCRPC patients before treatment initiation with abiraterone (n=56) or enzalutamide (n=29) were analyzed via droplet digital polymerase chain reaction. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The association of AR-V7 status with prostate-specific antigen (PSA) response defined by PSA decline ≥50% and with PSA-progression-free survival (PSA-PFS), clinical PFS, and overall survival (OS) was assessed. RESULTS AND LIMITATIONS: High AR-V7 expression levels in whole blood were detectable in 18% (15/85) of patients. No patient with high AR-V7 expression achieved a PSA response, and AR-V7 status was an independent predictor of PSA response in multivariable logistic regression analysis (p=0.03). High AR-V7 expression was associated with shorter PSA-PFS (median 2.4 vs 3.7 mo; p<0.001), shorter clinical PFS (median 2.7 vs 5.5 mo; p<0.001), and shorter OS (median 4.0 vs. 13.9 mo; p<0.001). On multivariable Cox regression analysis, high AR-V7 expression remained an independent predictor of shorter PSA-PFS (hazard ratio [HR] 7.0, 95% confidence interval [CI] 2.3-20.7; p<0.001), shorter clinical PFS (HR 2.3, 95% CI 1.1-4.9; p=0.02), and shorter OS (HR 3.0, 95% CI 1.4-6.3; p=0.005). CONCLUSIONS: Testing of AR-V7 mRNA levels in whole blood is a simple and promising approach to predict poor treatment outcome in mCRPC patients receiving abiraterone or enzalutamide. PATIENT SUMMARY: We established a method for determining AR-V7 status in whole blood. This test predicted treatment resistance in patients with metastatic castration-resistant prostate cancer undergoing treatment with abiraterone or enzalutamide. Prospective validation is needed before application to clinical practice.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Seitz AK, Thoene S, Bietenbeck A, et al. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide. Eur Urol. 2017. PMID: 28818355. doi:10.1016/j.eururo.2017.07.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。